Tislelizumab injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Brand: Baizean
Company: BeiGene
Medicine type: Biologic
Therapeutic area: Oncology
Indications recorded in the public source: 1. For relapsed or refractory classical Hodgkin lymphoma after at least two lines of systemic chemotherapy. 2. For PD-L1-high locally advanced or metastatic urothelial carcinoma after failure of platinum-based chemotherapy, including progression within 12 months of neoadjuvant or adjuvant chemotherapy. 3. With paclitaxel and carboplatin, or albumin-bound paclitaxel and carboplatin, as first-line treatment of unresectable locally advanced or metastatic squamous NSCLC. 4. With pemetrexed and platinum-based chemotherapy as first-line treatment of unresectable locally advanced or metastatic nonsquamous NSCLC with negative EGFR mutation and ALK status. 5. Monotherapy for adults with locally advanced or metastatic nonsquamous NSCLC with negative EGFR mutation and ALK status that has progressed after or is intolerant of platinum-based chemotherapy; also for adults with locally advanced or metastatic squamous NSCLC with negative or unknown EGFR and ALK status that has progressed after or is intolerant of platinum-based chemotherapy. 6. With platinum-based chemotherapy as neoadjuvant treatment, followed after surgery by tislelizumab monotherapy as adjuvant treatment, for resectable stage II or IIIA NSCLC. 7. With etoposide and platinum-based chemotherapy as first-line treatment of extensive-stage small cell lung cancer. 8. Monotherapy as first-line treatment of unresectable or metastatic hepatocellular carcinoma. 9. For advanced hepatocellular carcinoma after sorafenib, lenvatinib or oxaliplatin-containing systemic chemotherapy. 10. For adults with unresectable or metastatic MSI-H or dMMR advanced solid tumors: advanced colorectal cancer that has progressed after a fluoropyrimidine, oxaliplatin and irinotecan; or other advanced solid tumors that have progressed after prior treatment and have no satisfactory alternative treatment. 11. With paclitaxel and a platinum agent, or a fluoropyrimidine and a platinum agent, as first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma. 12. For locally advanced or metastatic esophageal squamous cell carcinoma that has progressed after or is intolerant of first-line standard chemotherapy. 13. With gemcitabine and cisplatin as first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. 14. With fluoropyrimidine- and platinum-based chemotherapy as first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Indication source and scope: Source date(s): 2025, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
Prescribing-information limitations: A verifiable complete prescribing-information document has not yet been obtained. Available approval records or NHSA submissions support the indications shown; the latest full scope needs confirmation.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Canada: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Restricted to: 1. For PD-L1-high locally advanced or metastatic urothelial carcinoma after failure of platinum-based chemotherapy, including progression within 12 months of neoadjuvant or adjuvant chemotherapy. 2. With paclitaxel and carboplatin, or albumin-bound paclitaxel and carboplatin, as first-line treatment of unresectable locally advanced or metastatic squamous NSCLC. 3. With pemetrexed and platinum-based chemotherapy as first-line treatment of unresectable locally advanced or metastatic nonsquamous NSCLC with negative EGFR mutation and ALK status. 4. For adults with locally advanced or metastatic nonsquamous NSCLC with negative EGFR mutation and ALK status that has progressed after or is intolerant of platinum-based chemotherapy; also for adults with locally advanced or metastatic squamous NSCLC with negative or unknown EGFR and ALK status that has progressed after or is intolerant of platinum-based chemotherapy. 5. With platinum-based chemotherapy as neoadjuvant treatment, followed after surgery by tislelizumab monotherapy as adjuvant treatment, for resectable stage II or IIIA NSCLC. 6. With etoposide and platinum-based chemotherapy as first-line treatment of extensive-stage small cell lung cancer. 7. First-line treatment of unresectable or metastatic hepatocellular carcinoma. 8. For advanced hepatocellular carcinoma after sorafenib, lenvatinib or oxaliplatin-containing systemic chemotherapy. 9. For adults with unresectable or metastatic MSI-H or dMMR advanced solid tumors: advanced colorectal cancer that has progressed after a fluoropyrimidine, oxaliplatin and irinotecan; or other advanced solid tumors that have progressed after prior treatment and have no satisfactory alternative treatment. 10. With paclitaxel and a platinum agent, or a fluoropyrimidine and a platinum agent, as first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma. 11. For locally advanced or metastatic esophageal squamous cell carcinoma that has progressed after or is intolerant of first-line standard chemotherapy. 12. With gemcitabine and cisplatin as first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. 13. With fluoropyrimidine- and platinum-based chemotherapy as first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Insurance period: 2026-01-01 to 2027-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions